Tuesday Nov 26
The Motley Fool
The Good News, Bad News for Belviq: a Now the Good News
Belviq, Arena Pharmaceuticals ' lead obesity drug, continues to rack up mediocre sales numbers as sales performance continues to lag expectations.
Obesity drugs result in greater weight loss
Did you know eating more fruit could help you lose weight? But choose the fruit wisely.
VIVUS Announces Issuance of Two Key U.S. Patents for Qsymia; Patent...
VIVUS,Inc. , a biopharmaceutical company commercializing Qsymia capsules CIV for the treatment of obesity, today announced that the United States Patent and Trademark Office has issued U.S. Patent Nos.
VIVUS, Inc. Announces Scientific Presentations
VIVUS,Inc. , a biopharmaceutical company commercializing QsymiaA capsules CIV for the treatment of obesity, today announced the following scientific presentations in connection with Obesity Week 2013: Pre-Conference Early Development Pharmacologic and Device Session for Up and Coming Obesity Treatments Date/Time Tuesday, November 12, 2013, 12:00 pm ... (more)
Bearish Movers: VIVUS, Inc. (NASDAQ:VVUS), First Solar, Inc....
StockMarketIntel.com issues a special report on the following stocks: VIVUS, Inc. , First Solar, Inc. , Eco-Tek Group Inc , Electrolux AB VIVUS, Inc. declined -0.99% recently, while trading on 291,933 shares at the price of $9.00.